223 results about "Aids diagnostics" patented technology

The invention belongs to the fields of genetic engineering and oncology, and discloses a blood serum/blood plasma micro ribonucleic acid (miRNA) marker relevant with pancreatic cancer and application thereof. The marker is formed by combining miR-451 and miR-490-3p. The marker and primers of the marker can be used for preparing a diagnostic kit and are used for the auxiliary diagnosis of pancreatic cancer.

The invention belongs to the field of genetic engineering and phymatology, in particular to a blood serum/blood plasma miRNA marker related to non-small cell lung cancer (SCLC) prognosis and an application thereof. The marker is one or more of miR-486, miR30d, miR-1 or miR-499 and can be used for preparing an auxiliary diagnostic reagent kit for the non-SCLC prognosis or a medicine for treating the SCLC.

The invention discloses a lung cancer diagnosis system based on multiple machine learning algorithms, and relates to the field of medical instruments, and the system comprises a preliminary predictionmodule which is used for employing a plurality of trained lung cancer prediction models to perform lung cancer preliminary prediction processing of lung clinical data of a to-be-diagnosed patient, and obtaining a plurality of lung cancer preliminary prediction results, and a lung cancer diagnosis module used for carrying out lung cancer classification processing on the plurality of lung cancer preliminary prediction results by utilizing a trained lung cancer meta-classifier, and determining whether the patient to be diagnosed is a lung cancer patient or not. The system can be applied to the process of clinical auxiliary diagnosis of lung cancer and helps clinicians to make decisions, information can be shared to a plurality of centers through a network platform, diagnosis suggestions canbe provided for clinicians lacking experience, and the overall clinical lung cancer diagnosis level is improved.

The invention establishes a circRNA expression profile for a patient with craniosynostosis, provides, provides serum circRNA marker hsa_circ_0001788 for the patient with craniosynostosis, discloses diagnostic value of hsa_circ_0001788 of serum for craniosynostosis, applies the marker herein to prepare a diagnostic kit for the patient with craniosynostosis, and provides supporting for clinical early discovery and treatment of the patient with craniosynostosis. Serum circRNA has good stability, degradation difficulty and the other advantage, has high value in auxiliary diagnosis, and is easy toclinically popularize and use. A circRNA chip is used herein to carry out detecting to obtain disease-specific and abnormally-expressed serum circRNA expression profiles; verifying is performed by means of qRT-PCR; a strict design and evaluation system is provided. It is discovered for the first time that the marker hsa_circ_0001788 in serum is an important biological detection index which causesminimal invasion and has low cost and which is applicable to clinical detection; the marker hsa_circ_0001788 is important to the clinical early diagnosis and differential diagnosis of craniosynostosis; a new idea is provided for the diagnosis of craniosynostosis in molecular level, and it is expected that early diagnostic rate of craniosynostosis is increased.

The invention discloses biomarkers for diagnosing endometrial cancer as well as a product and application thereof, and provides application of reagents for detecting biomarkers TMSB10, EIF3E and PDIA6 in a sample to be detected in preparation of the product for diagnosing and/or assisting in diagnosing endometrial cancer. Verification results show that the combination of TMSB10, EIF3E and PDIA6 has relatively good diagnosis efficiency, whether a subject suffers from the endometrial cancer or the risk of suffering from the endometrial cancer or not can be diagnosed in an early stage according to the combination of TMSB10, EIF3E and PDIA6, and good clinical application value is achieved.

The invention belongs to the field of genetic engineering and medicine, relates to a novel tumor marker for early diagnosis of pancreatic cancer, and more specifically discloses a new serum/tissue tumor marker associated with pancreatic cancer and application thereof. The marker is a combination of CystatinSN (CST1), CystatinS (CST4) and CystatinSA (CST2). The marker, primers and antibodies can be used for a diagnostic kit for the auxiliary diagnosis of pancreatic cancer.

The invention belongs to the field of biological medicine and specifically relates to various RNAs, various combinations of tumor markers thereof and an application thereof in preparing a gastric cancer diagnosis reagent. The invention provides a set of new RNA molecular markers for gastric cancer diagnosis. The content of the set of RNA in gastric cancer tissue is higher than the content of para-carcinoma tissue and the content of the set of RNA in the plasma of gastric cancer patient is higher than the content thereof in the plasma of healthy people. The invention also provides a method for taking one or different combinations of the set of RNA as the tumor markers and the application thereof. The set of RNA molecular marker and the diagnostic method of different combinations of the set of RNA markers adopted for diagnosing gastric cancer are simple in operation, are convenient in material taking and have the characteristics of high specificity, high sensitivity and easiness in mass screening. The set of RNA molecular marker is fit for screening of gastric cancer high-risk groups and auxiliary diagnosis of gastric cancer.

The invention discloses application of miR-425 in tumor diagnosis, treatment and prognosis. Multiple biological characteristics of tumor including apoptosis, proliferation, drug susceptibility and the like disclosed by the invention are closely related to the expression quantity of miR-425. MiR-425 antagonist antimiR-425 can be used for significantly inhibiting proliferation of multiple types of tumor cells and the tumorigenic ability of the tumor cells in a nude mouse, and enhancing the tumor treatment capacity of chemotherapy drug cisplatin and the like in the nude mouse. The invention discloses a kit for tumor assisted diagnosis and patient survival prognosis, and the kit contains a primer sequence for the quantitative determination of miR-425; the invention also discloses a pharmaceutical composition for treating tumor, wherein the composition contains the miR-425 antagonist antimiR-425. The invention provides a novel method for assisted diagnosis and prognosis diagnosis of cancer. The invention discovers that the antimiR-425 has high clinical application value in the preparation of a tumor-treating medicine, and particularly provides a novel medicine and a treatment method for the effective treatment of lung cancer and liver cancer.

The invention discloses a reagent kit for detecting lymphoma genovariation and an application of the reagent kit, and particularly discloses the reagent kit for detection or auxiliary detection of variation of a lymphoma related gene. The reagent kit comprises a substance for detecting BCL2,BCL6, MYC and/or gene IGH fusion, the substance is a complete set of DNA probes, and the complete set of theDNA probes comprises 376 probes as shown in SEQID NO:1 to SEQ ID NO:376. The reagent kit can be used for detection or auxiliary detection of the variation of the lymphoma related gene, substyping ofcells of origin (cell of origin, COO) of patients suffering from diffuse large B-cell lymphoma, and auxiliary diagnosis, prognostication judging and/or targeted drug prediction of the patients suffering from lymphoma.

The present invention discloses a detection marker of steroid-induced osteonecrosis of femoral head necrosis and an application thereof. RNA expression levels of 6 genes of NPNT, KDM5D, BOLA2, EIFYAY,RPS4Y1 and PPKY are down-regulated in SIONFH patients for the first time. The detection marker lays a good foundation on preparing a kit for diagnosis or auxiliary diagnosis of SIONFH.

The invention provides a detection kit for detecting a biomarker of the bladder cancer. The detection kit includes a primer and probe for detecting the biomarker of the bladder cancer, the biomarker of the bladder cancer is at least one selected from genes of CA9, IGF2, CDK1, UBE2C, CRH, RPS21 and HOXA13. Furthermore, the detection kit further includes a primer and probe for detecting a referencegene, the reference gene is selected from SLC25A6, ACTB or GAPDH. The invention also provides a bladder cancer-diagnosing diagnostic kit including the detection kit. The diagnostic kit is capable of diagnosing whether an individual has the bladder cancer or not and the possibility of recurrence accurately, and has high sensitivity, and the functions of auxiliary diagnosis and recurrence monitor ofnon-invasive bladder cancer are achieved.

The invention relates to the field of medical examination, and particularly relates to a sample dilution composition for detecting a sugar antigen 72-4, a detection reagent and a kit containing the detection reagent. The kit mainly comprises a magnetic particle suspension coated with a CA72-4 antibody, an enzyme conjugate, a sample diluent and a calibrator. The sample dilution composition can be used for auxiliary diagnosis and postoperative monitoring of tumor diseases such as gastric cancer, ovarian cancer, colorectal cancer, pancreatic cancer and cervical cancer. The kit is short in detection time, and the time of an inspector is greatly saved; the kit adopts a double-antibody sandwich method, is wide in linear range and high in clinical practicability; the kit adopts the specific sample diluent, so that the difference between new and old samples can be eliminated, false positive interference caused by HAMA is effectively reduced, and the detection accuracy of CA72-4 is greatly improved; and the kit adopts a two-step method, so that the risk of HOOK in clinical practice is reduced.

The invention provides a use of a combined serum metabolic marker in the preparation of a kit for diagnosing the progress of hepatopathy, the kit, and a method using the kit to screen serum metabolicmarkers, and relates to the technical field of serum metabolic markers. The combined serum metabolic marker is mainly composed of sodium glycochenodeoxycholate sulfate, glycochenodeoxycholic acid, glycodesoxycholic acid, glycocholic acid and taurochenodeoxycholic acid. The kit executes combined screening detection on the content of above serum metabolites in serum in order to realize assisted diagnosis of the progress of the hepatopathy of hepatopathy patients, so the difficult monitoring problem of the occurrence and development of the hepatopathy in existing clinic therapy of the hepatopathyis effectively alleviated.

The invention discloses a blood vessel, artery and vein identification method for fundus photography. Each position in the fundus photography is automatically positioned and measured to achieve an effect on pre-screening diseases, pictures with lesion suspicions can be automatically screened so as to accurately and effectively carry out mark identification on blood vessel contours and blood vesselarteries and veins, then, the diameter ratio of arteries and veins can be calculated to assist in diagnosing diseases, including retina blood vessels and the like, and the workloads of doctors are reduced. In addition, the result of the method does not depend on the experience of doctors and is more objective, doctors can be effectively assisted in diagnosing diseases, and a purpose of remote consultation is realized.

The invention discloses a stent for assisting computed tomography (CT) diagnosis of tarsometatarsal joint injury. The stent comprises a stent main body, a foot fixer, a pedal, an inner tube and an adjusting piece, wherein the inner tube is fixedly arranged on the stent main body; the adjusting piece is arranged on the inner tube in a rotatable and sliding mode; and both the foot fixer and the pedal are fixedly connected with the adjusting piece. The stent for assisting the CT diagnosis of the tarsometatarsal joint injury can assist a patient in maintaining a foot at a plantar flexion ectropion position in the CT diagnosis process, so that diagnosis is facilitated, the requirement of the CT diagnosis for the flexion direction of the foot of the patient is met, the CT diagnosis operation can be accurately performed, and the accuracy and the precision of the diagnosis result are ensured.

The invention discloses a traditional Chinese medicine auxiliary diagnosis system. The system comprises a data acquisition module used for acquiring a traditional Chinese medicine diagnosis text and acorresponding disease and constructing a training set; a model construction module used for respectively training the bidirectional LSTM network and the BERT network according to the training set, and constructing a traditional Chinese medicine auxiliary diagnosis model according to the trained bidirectional LSTM network and BERT network; and a disease prediction module used for predicting the to-be-detected traditional Chinese medicine diagnosis text according to the traditional Chinese medicine auxiliary diagnosis model and outputting a predicted disease. A traditional Chinese medicine auxiliary diagnosis model is constructed in combination with a bidirectional LSTM network and a BERT network, the problems that traditional Chinese medicine professional vocabulary expression is limited in traditional Chinese medicine diagnosis data and contextual information in traditional Chinese medicine texts cannot be fully utilized are solved, and corresponding diseases are predicted and diagnosed according to traditional Chinese medicine clinical symptoms.

The invention discloses a diagnostic agent for diagnosis or auxiliary diagnosis of renal insufficiency or renal injury, a kit and application, and relates to the technical field of renal insufficiencyor renal injury diagnosis. The diagnostic agent disclosed by the invention comprises a detection reagent for detecting the expression level of RPS7 gene and/or the SRP14 gene. Researches find that the RPS7 gene and the SRP14 gene have the characteristic of high expression in a renal insufficiency or renal injury group, can be used as markers for renal insufficiency or renal injury diagnosis or auxiliary diagnosis, and provide a new thought and method for renal insufficiency or renal injury diagnosis or auxiliary diagnosis.

The invention discloses a specific primer combination for identifying RET gene mutation of medullary thyroid carcinoma. The specific primer combination is characterized in that the combination is usedfor amplifying a sequence shown in SEQ ID NO.1 in RET gene mutation of medullary thyroid carcinoma. The primer combination comprises a combination of a primer RET8, a primer RET10, a primer RET11, aprimer RET13, a primer RET14, a primer RET15 and a primer RET16. The invention further discloses a kit of the primer combination and an application of the primer combination. The primer combination ishigh in specificity, covers targeted area fragments accurately and detects various known mutant sites. By adopting a mixed solution of the specific primers and marks with fluorescent edges to carry out PCR amplification on batched samples and sanger sequencing analysis, a lot of samples can be analyzed at one time, and various known and unknown mutation can be detected, so that the operating steps are reduced, the resources are saved and the efficiency is improved. A kit provided by the invention can be widely applied to assisted diagnostic detection of clinical medullary thyroid carcinoma and has a wide application prospect.

The invention discloses an automatic evaluation system for aerobic capability and a cardiopulmonary clinic symptom. The system comprises the following modules of: aerobic capability evaluating equipment, a network connecting module, an evaluating and decision module, a model database, and result output modules (printer, remote medical interface, and Internet interface). A doctor can use the aerobic capability evaluating equipment for evaluating a patient. Evaluation data are uploaded to the remote evaluating and decision module through a wired or wireless relay network. The evaluating and decision module generates auxiliary diagnosis information according to a data acquisition result and the model database and outputs the auxiliary diagnosis information to related personnel.

The invention discloses a diagnosis method of an auxiliary diagnosis model based on a disease binary classifier. The diagnosis method comprises the following steps: S1, data preprocessing; S2, model training; S3, diagnosing and predicting. According to the method, diagnosis prediction is defined as a text classification task, namely, for an input patient EHR, information such as chief complaint, current medical history and iconography is extracted, whether a patient suffers from diseases or not is predicted by training a binary classifier (BiLSTM + Self-Attention model) of multiple diseases, and finally prediction of patient diagnosis is obtained so as to assist a doctor in making a later decision.

The invention relates to a polypeptide, a detection device containing the polypeptide and a diagnostic kit containing the detection device. By applying the kit to the early screening and clinical auxiliary diagnosis of human enterovirus 71, a satisfactory effect can be achieved.

The invention relates to the technical field of biological and medical detection, and particularly relates to a time-resolved fluorescence immunoassay kit for comprehensively detecting uterine cancer tumor markers SCC (Squamous Cell Carcinoma), CEA (Carcinoma Embryonic Antigen), CA125 (Carcinoma Antigen 125), and beta-HCG (Human Chorionic Gonadotropin) simultaneously in a same reaction system, and further relates to application of the kit in comprehensive detection of the uterine cancer tumor markers SCC, CEA, CA125, and beta-HCG simultaneously. The kit comprises a first monoclonal antibody mixed antibody coated microplate for respectively resisting SCC, CEA, CA125, and beta-HCG, a second monoclonal antibody mixed antibody of Eu<3+> labeled anti-SCC, Sm<3+> labeled anti-CEA, Tb<3+> labeled anti-CA125 and Dy<3+> labeled anti-beta-HCG, an analytical buffer solution, a common fluorescence reinforcing agent, a washing liquid and a quality control product. The kit related by the invention can be used in clinical auxiliary diagnosis, curative effect observation, and prognosis judgment of the uterine cancer, has a great significance on the treatment and prevention of the uterine cancer, and can be used for detecting the four tumor markers simultaneously, thereby simplifying detection steps, and improving the specificity and the sensitivity of the comprehensive analysis of detection data.

The invention discloses an auxiliary diagnosis device for medical care radiation. The auxiliary diagnosis device comprises a bed board, wherein bed frames are respectively arranged on two sides of thebed board; a universal wheel is arranged at the bottom of each bed frame; a storage box is arranged at the upper part of the bed frame; a lead and rubber protection apron is placed in the storage box, and consists of a plurality of apron cloths; tying belts are respectively arranged on two sides of the apron cloths; a first cylinder and a second cylinder are separately arranged at two ends of thebed board; and the first cylinder is connected with a first sliding block through an air cylinder effecting end, and the other side of a fixing plate block is connected with a rear moving bed board.According to the auxiliary diagnosis device disclosed by the invention, a patient can be subjected to omnidirectional safety protection, the pertinence is high, the protection is comprehensive, and the height and the oblique degree of the bed board can be adjusted in a real-time manner according to the situation of different patients, so that the purpose of adjusting the body position of the patient is achieved, the requirements for radiation diagnosis and treatment can be better met, the patient can communicate with medical personnel in time, and the working efficiency of diagnosis and treatment is improved.